Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
|
CN |
|
Beijinghualian Hypermarket Co Ltd
SSE:600361
|
CN |
|
Wuchan Zhongda Group Co Ltd
SSE:600704
|
CN |
|
J
|
JY Grandmark Holdings Ltd
HKEX:2231
|
CN |
Jiangsu GDK Biotechnology Co Ltd
Jiangsu gdk Biotechnology Co., Ltd. engages in the research and development, production, and sale of human vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 421 full-time employees. The company went IPO on 2021-08-02. The Company’s main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The firm's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The firm distributes its service within the domestic market.
Jiangsu gdk Biotechnology Co., Ltd. engages in the research and development, production, and sale of human vaccines. The company is headquartered in Taizhou, Jiangsu and currently employs 421 full-time employees. The company went IPO on 2021-08-02. The Company’s main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The firm's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The firm distributes its service within the domestic market.
